BioCardia Clinical Trial Data
BioCardia announced it will present the trial design and scientific support for its CardiAMP HF II Study at the Heart Failure Society of America Annual Scientific Meeting. The study evaluates a high-dose autologous cell treatment for patients with ischemic heart failure of reduced ejection fraction (HFrEF) who remain symptomatic despite medical therapy.
- Counterparty
- Heart Failure Society of America